CoreCap Advisors’s ProPhase Labs PRPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $0 | Hold |
10
| – | – | ﹤0.01% | 3312 |
|
|
2026
Q2 | $1 | Hold |
10
| – | – | ﹤0.01% | 3168 |
|
|
2026
Q1 | $1 | Sell |
10
-710
| -99% | -$257 | ﹤0.01% | 2932 |
|
|
2025
Q4 | $322 | Buy |
720
+710
| +7,100% | +$2K | ﹤0.01% | 2761 |
|
|
2025
Q3 | $46 | Sell |
10
-340
| -97% | -$1.31K | ﹤0.01% | 2758 |
|
|
2025
Q2 | $1.37K | Hold |
350
| – | – | ﹤0.01% | 2379 |
|
|
2025
Q1 | $1.42K | Buy |
350
+340
| +3,400% | +$1.56K | ﹤0.01% | 2446 |
|
|
2024
Q4 | $76 | Hold |
10
| – | – | ﹤0.01% | 2784 |
|
|
2024
Q3 | $242 | Hold |
10
| – | – | ﹤0.01% | 2475 |
|
|
2024
Q2 | $418 | Hold |
10
| – | – | ﹤0.01% | 1462 |
|
|
2024
Q1 | $647 | Buy |
+10
| New | +$507 | ﹤0.01% | 2293 |
|
|
2022
Q4 | $963 | Buy |
+10
| New | +$1.08K | ﹤0.01% | 2059 |
|
|
2022
Q3 | – | Sell |
-10
| Closed | -$1K | – | 1672 |
|
|
2022
Q2 | $1K | Buy |
+10
| New | +$879 | ﹤0.01% | 2037 |
|
|
2022
Q1 | – | Sell |
-10
| Closed | -$1K | – | 1676 |
|
|
2021
Q4 | $1K | Buy |
+10
| New | +$622 | ﹤0.01% | 2207 |
|
CoreCap Advisors's PRPH Position: Q3 2026 in Review
CoreCap Advisors held its ProPhase Labs (PRPH) position steady in Q3 2026 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3312.
CoreCap Advisors first reported a position in PRPH in Q4 2021 and has held it in 14 quarters since. The position peaked at $1.42K in Q1 2025. 2 funds tracked by Wall St. Rank hold PRPH as of Q3 2026.
- CoreCap Advisors held 10 shares of ProPhase Labs worth $0 as of Q3 2026.
- CoreCap Advisors left its ProPhase Labs share count unchanged in Q3 2026.
- ProPhase Labs made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #3312 holding.
- CoreCap Advisors first reported a position in ProPhase Labs in Q4 2021 and has held it in 14 quarters since.
- CoreCap Advisors's ProPhase Labs position peaked at $1.42K in Q1 2025.
- 2 funds tracked by Wall St. Rank held ProPhase Labs as of Q3 2026.
Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.